Wells Fargo analyst Derek Archila reiterated a Hold rating on Viridian Therapeutics (VRDN – Research Report) yesterday and set a price target of $27.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Derek Archila has given his Hold rating due to a combination of factors surrounding Viridian Therapeutics’ current and future prospects. The company is progressing with its pipeline, particularly with VRDN-006 and VRDN-003, but there is limited immediate upside expected from VRDN-006’s Phase 1 data in the third quarter of 2025. The stock is anticipated to trade within a range until the Phase 3 data for VRDN-003 is released in the first half of 2026, which is seen as a key catalyst for the company’s shares.
Additionally, while Viridian’s commercial activities for Veligrotug are underway, with a potential U.S. launch in 2026, the market remains competitive. The company’s financial position is stable, with sufficient cash to support its operations into the second half of 2027. However, the lack of significant catalysts in 2025 and the performance of Tepezza have been weighing on the stock, which has underperformed compared to the broader market index. As such, Archila believes the stock setup may improve closer to the 2026 data readouts, justifying the Hold rating at this time.
VRDN’s price has also changed dramatically for the past six months – from $24.270 to $12.030, which is a -50.43% drop .